Pouromec

Quick links to important sections

Pouromec

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pouromec

Property Description
Active Ingredient Ivermectin
Form Solution (Pour-on)
Pharmacological Class Antiparasitic Agent / Endectocide
General Purpose Control of parasitic infestations in livestock (internal and external)
Origin Semi-synthetic (Macrolide / Avermectin derivative)

What Type of Preparation is Pouromec?

Pouromec is a specialized veterinary medicinal solution containing the active substance, Ivermectin (INN). Ivermectin is clinically recognized as an Endectocide, a term that signifies its broad and dual activity against both internal worms and external parasitic organisms. This compound belongs to the macrocyclic lactone class of agents. The substance is a semi-synthetic derivative of the avermectins, a group characterized by their potent and extensive antiparasitic capabilities. The designation of Pouromec as an Endectocide provides a basis for its use in comprehensive parasitic management across susceptible livestock populations.

Composition and Delivery Form

The product is formulated as a liquid solution designed for non-invasive topical pour-on administration, differentiating it from oral or injectable alternatives. Pouromec utilizes Ivermectin as its single active ingredient, suspended within a specialized vehicle that facilitates absorption through the skin following application. The pour-on route is specifically selected because it allows the active ingredient to be distributed systemically throughout the body, ensuring coverage necessary to control both internal and external parasitic challenges. The substance is formulated for systemic action against susceptible targets via this delivery route.

General Purpose and Broad Mechanism

The general purpose of the preparation is to provide effective control over susceptible parasitic infestations in livestock. The mechanism relies on Ivermectin selectively interfering with neuro-signals specific to invertebrates, primarily by binding to and disrupting the parasites' nerve and muscle function. This targeted action leads to the sustained paralysis and subsequent elimination of the infestation, aligning with the product's role as a powerful, broad-spectrum antiparasitic solution.

What side effects are possible with Pouromec?

Possible side effects and safety information

The official safety information for Ivermectin pour-on formulations categorizes adverse reactions based on their nature and the organ systems involved, emphasizing label-documented constraints for safe application and public health.

Frequency and Organ Class Classification

The most frequently documented adverse events relate to the product's delivery route. Local transient skin reactions are common and are classified under Disorders of the Skin and Subcutaneous Tissue. These include irritation, scaling, pruritus (itching), and temporary alopecia (hair loss) at the application site.

Less frequently, or with incidence classified as uncommon or rare, are more systemic effects. These fall under Nervous System Disorders (e.g., ataxia, recumbency, paralysis) and Immune System Disorders (hypersensitivity). Serious adverse reactions documented in regulatory sources include anaphylactoid reactions and severe neurological signs.

Official Safety and Population Constraints

Safety is defined by mandatory restrictions, which are a key component of the official profile. The product is not approved for use in female dairy cattle of breeding age or within 60 days of calving, a constraint related to public health concerns. The label also specifies that the solution is for topical application only and must not be administered by other routes, as severe adverse reactions, including fatalities, have been documented in non-target species.

Time-related safety patterns note that the common skin reactions are transitory and self-limiting. Treatment timing is also critical: for instance, adverse neurological outcomes associated with the killing of specific migrating larvae are officially documented to occur when treatment is administered during certain periods of the year.

Overdose and Emergency Response

The official regulatory profile for Ivermectin overdose describes a spectrum of documented manifestations and severe outcomes, requiring immediate emergency response. Symptoms of overexposure may initially present as gastrointestinal effects, including nausea, vomiting, diarrhea, and abdominal pain, often accompanied by dermal signs such as rash, edema, or urticaria. Neurological manifestations like headache, dizziness, and generalized weakness (asthenia) are also officially noted in regulatory documents.

Overdose can progress to severe or life-threatening outcomes. The most serious documented risks involve Central Nervous System (CNS) depression, which can manifest as ataxia, confusion, stupor, and potentially escalate to seizure or coma. Cardiopulmonary issues such as hypotension (low blood pressure) and dyspnea (difficulty breathing) have also been reported, with death listed as a possible consequence in cases of severe toxicity.

Due to the severity of these documented effects, official regulatory guidance mandates that individuals must seek immediate medical attention for any signs or symptoms of overexposure, including contacting poison control or emergency services. Management is defined as supportive therapy since no specific antidote is known for Ivermectin overexposure. Supportive measures, which are detailed in prescribing information, may include procedures such as gastric lavage, administration of parenteral fluids and electrolytes, and the use of pressor agents to manage severe hypotension. The official profile also notes that toxicity reports include accidental human exposure to concentrated veterinary formulations like pour-on products.

Therapeutic Uses of Pouromec

Pouromec is an Endectocide that is commonly used in the management of internal and external parasitic infestations that create noticeable physiological strain on livestock. Its role is focused on helping manage the diverse symptom patterns associated with these parasitic challenges.

The preparation is relevant for a wide range of parasitic infections and infestations, specifically including gastrointestinal roundworms, lungworms, sucking and biting lice, mange mites, and cattle grubs.

Control of Internal Parasites and Systemic Decline

This therapeutic domain is relevant for managing parasitic roundworms that manifest in the gastrointestinal tract and the lungs. The medication helps manage debilitating symptoms such as severe weight loss, chronic scours, and anemia caused by these internal infestations, and contributes to improved nutrient absorption and supports the animal's overall physical vitality.

Management of External Infestations and Dermal Distress

Pouromec is also applied to treat infestations caused by common external parasites, including mites and lice. This use supports the easing of pronounced dermal distress symptoms like intense pruritus, hair loss, and inflammation, contributing to the animal's comfort and supports the easing of symptoms related to coat quality.

Provision of Broad-Spectrum and Sustained Protection

The preparation is used for addressing both classes of parasites—internal and external—with a single application, providing a broad-spectrum intervention. This comprehensive action may contribute to lessening the clinical burden associated with recurring parasitic disease.

Quick Fact: Supportive Management for Parasite-Induced Itching This preparation is relevant in scenarios involving significant dermal distress caused by ectoparasites, and supports animals during episodes of heightened discomfort and may assist with maintaining functional stability.

Regulatory References

  1. Health Canada Product Monograph

Eligibility and Restrictions for Use

The eligibility profile for Pouromec (Ivermectin Pour-on) is defined strictly by regulatory documents that classify who may and may not use the veterinary medicine.

Populations Prohibited from Use

Use of Pouromec is formally contraindicated in humans, as the product is formulated specifically for animal use. It is also contraindicated for female dairy cattle of breeding age and for calves intended to be processed for veal. These prohibitions are in place primarily because a required drug residue withdrawal time has not been established for milk and for the specific physiological stage of veal calves. Furthermore, the medicine is not recommended for species other than cattle.

Conditional and Restricted Use

The product's regulatory approval includes specific restrictions based on the animal's reproductive status and environmental factors. Treatment is prohibited for non-lactating dairy cows within two months before the date of calving. Application must not occur when the cattle's hide or hair is wet, or when the application site contains lesions or adherent materials, as these conditions significantly reduce the medicine's effectiveness. Conditional use is also required when treating cattle for Hypoderma larvae (cattle grubs) to avoid severe host-parasite reactions during certain stages of the parasite's migration.

What should I know about interactions with other medicines?

The official interaction profile for this preparation is defined primarily by factors that modify drug exposure at the site of administration and by noted population susceptibility. No specific drug-drug combinations are listed in the regulatory labeling for the cattle pour-on product.

Exposure-Modifying and Timing Interactions

The systemic absorption and overall antiparasitic activity of the preparation are officially documented to be impaired by physical and environmental interactions. Efficacy is reduced if the pour-on is applied to an animal with wet hair or hide, or if the skin is covered by adherent materials such as caked mud or manure. The product must also be applied only to areas of the skin free from compromised dermal conditions, such as mange scabs or lesions.

This risk of physical interaction dictates a mandatory administration-timing rule: the preparation must not be used when rain or water exposure is expected to wet the cattle within six hours following treatment application. This restriction is enforced to ensure adequate time for the active substance to be systemically absorbed.

Population-Specific Interaction

The interaction profile includes a critical regulatory caution regarding species susceptibility. Due to the active substance's dependence on P-glycoprotein function, the product is not recommended for use in species other than cattle. This restriction stems from documented adverse reactions in sensitive dog breeds that possess a known P-glycoprotein deficiency, highlighting a significant pharmacogenetic interaction concern for the active compound.

Mechanism of Action

Selective Activation of Invertebrate Ion Channels

The active ingredient acts as a selective agonist for glutamate-gated chloride channels ( GluCls), which are unique to the nervous and muscle cells of susceptible invertebrates. This high-affinity binding causes these channels to open persistently, driving an unchecked chloride ion ( Cl^-) influx into the cell.

Mechanism of Flaccid Paralysis and Elimination

This sudden, continuous flow of Cl^- ions induces a state of electrical over-inhibition called hyperpolarization, effectively blocking all nerve impulse conduction and neuro-muscular transmission. The functional result is an irreversible flaccid paralysis of the parasite's essential systems, including its motility and feeding apparatus, resulting in its death and subsequent elimination.

Basis for Selective Toxicity and Limitations

Host protection is mediated by the host's P-glycoprotein ( P-gp) efflux pump, which actively removes the molecule from the host's central nervous system (CNS). However, the mechanistic action is constrained by the development of resistance mechanisms in parasites, often involving genetic mutations that reduce the binding affinity to the GluCl targets.

Dosage and Administration Information

How to Use Pouromec

Pouromec (Ivermectin Pour-On Solution) is administered according to a specific, standardized protocol. The method of use centers on a weight-dependent calculation and a specific topical application technique.


Official Administration Guidelines

Administration Scope Instruction
Route of Administration The product use is limited to topical pour-on application and is not for oral or injectable administration.
Dosing Schedule The dose rate is 500 mug of Ivermectin per kilogram of animal body weight (0.5 mg/kg). This volume is determined by an accurate measurement of the animal’s mass.
Frequency Pattern Usage involves a single application per treatment episode, adhering to a pre-determined parasite control schedule.

Procedural Structure and Conditions

Administration requires applying the measured dose to the dorsal midline of the animal, spanning from the withers to the tailhead. This is done on clean, dry skin. Reduced efficacy may occur if the hide is wet during treatment or if rain is anticipated within six hours of application.

Age-Group Administration Rules:

The medicine is not indicated for use in female dairy cattle of breeding age, nor is it for use in pre-ruminating calves destined for veal production.

This structured, weight-based topical protocol defines the way the solution is used, ensuring consistent application conditions across contexts.

Recent Clinical Evidence

Pouromec: Recent Clinical Evidence

Evidence for Parasite Control

Research for Ivermectin pour-on formulations, including Pouromec, is founded on Controlled Efficacy Trials and Randomized Controlled Trials (RCTs). These studies examine parasitic challenges in cattle populations and monitor outcomes related to physical well-being. For internal parasites, the research explores how parasite burdens are measured by tracking the Faecal Egg Count Reduction (FECR) percentage. Findings describe patterns observed where the formulation was associated with measurements of FECR and also reported patterns of higher weight gain in treated groups compared to untreated controls during the observation period.

For external parasites, the evidence describes studies that monitor direct parasite counts (lice, mites) and the elimination of larval stages (Cattle Grubs). Research describes patterns observed where trials reported changes in external parasite populations and also explored the duration of persistent control activity.

Research on Absorption and Uncertainty

Dedicated Bioequivalence (BE) studies and Pharmacokinetic (PK) trials have been used to examine how the active ingredient enters the bloodstream after pour-on application, confirming its systemic presence. Findings report patterns of significant individual variability in absorption among animals, sometimes related to licking behavior.

Certainty remains limited in several key areas. Evidence quality varies when assessing patterns related to emerging anthelmintic resistance across different regions. Also, the full extent of long-term effects beyond the initial study follow-up durations remains uncertain, and data is insufficient to fully characterize the sustained activity over multiple seasons.

Key Studies & References Ivermectin pour-on Product Monograph for Cattle, Health Canada

Frequently Asked Questions (FAQ)

Common questions about Pouromec (FAQ)

Q: Are headaches a common side effect of Pouromec?

A: Pouromec is a veterinary medicinal product that is contraindicated, or officially prohibited, for human use. The regulatory documents for this specific animal product list adverse reactions found in cattle, which include local skin reactions and neurological signs like paralysis. Official safety documents for the animal product do not list human-centric side effects such as headache.


Q: What happens if I miss a dose of Pouromec? (Non-dosing advice)

A: Pouromec is typically administered as a single, intermittent application according to a predetermined parasite control schedule for the intended species. Official regulatory labeling does not provide a standard procedure for dealing with a delayed application for cattle. Decisions regarding the timing of treatment should be determined by the prescribing veterinarian.


Q: Can Pouromec cause weight gain or weight loss?

A: According to official studies, Pouromec is designed to control parasitic infestations, which can positively impact animal health. Clinical evidence has examined outcomes related to effectiveness, and findings describe patterns of higher weight gain in treated animal groups compared to untreated control groups.


Q: What should I do if I accidentally take two doses close together? (Non-dosing advice)

A: Pouromec is a veterinary medicine and is not approved for human use. In the event of accidental human application or ingestion, official safety information states that contact with a poison control center or emergency services is necessary. High doses of the active ingredient may be associated with serious health effects.


Q: Can I drive or operate machinery while taking Pouromec?

A: As Pouromec is a veterinary product that is contraindicated for human use, official documents do not contain information or warnings regarding a person's ability to drive or operate machinery. These instructions are not provided because the medicine is not intended for people.


Q: Does Pouromec interact with alcohol? (Informational)

A: The official regulatory labeling for the veterinary Pouromec pour-on product does not list any specific interactions with alcohol. However, official information for human-use forms of the active ingredient typically notes that combining it with alcohol may be associated with an increased risk of certain side effects.


Q: What are the most commonly reported reasons for discontinuing Pouromec?

A: In the intended animal species, official documents describe that use may be discontinued due to mandatory regulatory constraints that prohibit its use in specific populations, such as female dairy cattle of breeding age. Discontinuation may also occur due to the rare occurrence of serious adverse reactions, such as neurological signs.


Q: What is the recommended storage temperature for Pouromec?

A: Official storage mandates require that Pouromec must be stored at or below 25 C (77 F). It must also be protected from direct sunlight, sources of ignition, and must not be frozen (stored below 0 C or 32 F).


Q: Is there a warning about suicidal thoughts or behavior with Pouromec?

A: Pouromec is a veterinary product that is contraindicated for human use. The official safety documents for this animal product list potential neurological adverse events in the intended species, such as ataxia and paralysis. However, the regulatory documents do not contain warnings regarding suicidal thoughts or behavior.


Q: Does Pouromec affect hormone levels?

A: Official regulatory documents do not directly state that Pouromec affects general hormone levels. However, the product's label includes warnings and restrictions regarding its use in specific reproductive populations, such as female dairy cattle of breeding age, related to food safety and regulatory constraints.


Q: Is Pouromec the same type of medicine as [similar drug name]?

A: Pouromec is an antiparasitic agent that is officially classified as an Endectocide. It belongs to the macrocyclic lactone class of drugs. This classification is based on its chemical structure and its defined mechanism of action against both internal and external parasitic organisms.


Q: Does Pouromec interact with common over-the-counter pain relievers?

A: The official regulatory labeling for the veterinary Pouromec pour-on product focuses on interactions that modify its absorption, such as applying it to wet skin. The label does not list any specific drug-drug combinations, including common over-the-counter pain relievers, that should be avoided in the intended animal species.


Q: Is it safe to take Pouromec with supplements like vitamins or herbal products?

A: The official regulatory labeling for the veterinary Pouromec pour-on product does not list specific drug-drug combinations that involve vitamins, supplements, or herbal products. Interactions described in the official documents primarily relate to environmental factors and species-specific susceptibility.


Q: Is Pouromec meant to be a short-term or long-term treatment?

A: Official administration guidelines describe Pouromec's use pattern as intermittent, often involving a single application per treatment episode. This pattern is aligned with its purpose for parasite control, suggesting non-continuous use rather than indefinite daily treatment.


Q: Is it normal to feel slightly dizzy when first starting Pouromec?

A: Pouromec is a veterinary product that is contraindicated for human use. While the official safety information lists neurological signs in the intended animal species, it does not provide information on dizziness or any other side effects for human users, as the product is not approved for people.


Q: Why do people sometimes stop taking Pouromec?

A: Official documents outline that reasons for stopping the use of Pouromec in the intended animal species include the mandatory regulatory constraints that prohibit its use in specific populations. Additionally, use may be stopped if serious adverse reactions, such as the neurological signs described in the safety information, are observed in the treated animal.


Q: Does Pouromec affect sleep patterns?

A: Pouromec is a veterinary product contraindicated for human use. The official regulatory documents for the animal product list systemic effects under Nervous System Disorders in the intended species. However, these documents do not list effects on sleep patterns.


Q: Can Pouromec make me feel more tired than usual?

A: Pouromec is a veterinary product contraindicated for human use. The official regulatory documents for the animal product list systemic effects under Nervous System Disorders in the intended species. These documents do not list tiredness or fatigue as a side effect.


Q: Are there any known severe allergic reactions associated with Pouromec?

A: Yes, the official safety information documents severe adverse reactions associated with the active ingredient. These reactions are classified under Immune System Disorders and include reports of anaphylactoid reactions and severe neurological signs in the intended animal species.


Q: What is the difference between Pouromec and a placebo in clinical trials?

A: Pouromec contains the active ingredient Ivermectin, which is formulated to control parasites. A placebo, or untreated control, is an inactive substance or group used for comparison in studies. Clinical trials examine the difference in specific health outcomes, such as parasite count reduction and weight gain patterns, between the group receiving Pouromec and the placebo control group.


Q: Can Pouromec be split or crushed if I have trouble swallowing pills?

A: Pouromec is formulated as a liquid solution for topical pour-on use in animals, not as a solid pill or tablet. The official route of administration is strictly for pour-on use on the skin. The product is explicitly forbidden for oral administration.


Q: Can Pouromec worsen existing conditions like depression or anxiety?

A: Pouromec is a veterinary product that is contraindicated for human use. The official safety documents for the animal product do not list depression or anxiety as adverse events, as the product is not approved for human patients.


Q: What kind of monitoring is typically required while taking Pouromec?

A: The monitoring described in official documents includes an accurate weight measurement of the animal prior to administration to ensure correct dosing. Additionally, observation is needed for the rare occurrence of adverse neurological outcomes, which have been documented when treating certain larvae stages during specific times of the year.


Q: Are there any long-term side effects associated with Pouromec use?

A: Official research evidence indicates that the full extent of long-term effects beyond the initial study follow-up durations remains uncertain. Regulatory data is currently considered insufficient to fully characterize the sustained activity over multiple seasons.


Q: What is the typical age range for people prescribed Pouromec?

A: Pouromec is a veterinary medicine that is contraindicated for human use. The official documents do not provide a typical age range for human prescription, as the medicine is formulated and approved only for use in animals.


Q: Is it common for Pouromec to cause digestive issues?

A: The official safety information for the animal product lists the most frequently documented adverse events as local transient skin reactions at the application site. Digestive issues are not listed among the commonly or less frequently reported systemic effects in the intended animal species.


Q: How does Pouromec compare to older treatments for the same condition? (High-level, non-comparative claim)

A: Pouromec contains Ivermectin, which is part of the macrocyclic lactone class of antiparasitic agents. Official documents describe this class as a semi-synthetic derivative supported by pharmacological studies for its potent and extensive antiparasitic capabilities, defining its place among treatment options.


Q: Why is my doctor asking me about other medicines I take before prescribing Pouromec?

A: Pouromec is an animal product contraindicated for human use. While the veterinary product label does not list drug-drug interactions, a healthcare provider typically asks about all current medications and supplements as a standard part of medical practice to identify potential interactions with any medicine you may be taking.


Q: Is Pouromec known to cause skin reactions or rashes?

A: Yes, the official safety information for the animal product indicates that the most frequently documented adverse events relate to the application site. These include local transient skin reactions such as irritation, scaling, itching, and temporary hair loss (alopecia) in the intended species.


Q: What is the role of the patient information leaflet for Pouromec?

A: The official product labeling, or patient information leaflet, is a document mandated by regulatory agencies. Its role is to provide complete and accurate information on the medicine's official use conditions, safety warnings, adverse reactions, and regulatory constraints, ensuring proper and compliant administration.

How should Pouromec be stored and disposed of?

How to Store and Dispose of Pouromec

Official regulatory documents define strict conditions for the storage and disposal of Ivermectin pour-on solution (the active component of Pouromec).

Storage and Stability Mandates

The solution must be stored at or below 25 C and protected from direct sunlight and sources of ignition. It is mandated to store the product in its original container, which must be kept tightly closed when not in use. The labeling prohibits storage at temperatures below 0 C (Do Not Freeze). The product must be stored out of the sight and reach of children.

Disposal Requirements

Disposal of the unused product and the empty container must be conducted in accordance with all local and national regulations. The product is documented as extremely hazardous to aquatic invertebrates; therefore, it must not contaminate water bodies, be disposed of into the sewage system, or be placed where it could reach water courses.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pouromec found in:

A-Z Index: